AviadoBio began enrolling a fourth dose-escalation cohort in its Phase 1/2 ASPIRE-FTD trial on 31 March 2026, the company said, after completing three cohorts in which 12 patients were dosed across five countries. The trial (NCT06064890) tests AVB-101, an adeno-associated virus 9 vector carrying a working copy of the GRN gene, given once as a bilateral infusion into the thalamus under real-time MRI guidance. The company reports 20 active sites in the United States, the United Kingdom, Canada and six European countries, dose-dependent rises in cerebrospinal fluid progranulin, no serious adverse events related to AVB-101 to date, and no need for prophylactic or reactive immunosuppression.

The peer-reviewed record is narrower. A study update published in Alzheimer's & Dementia on 25 December 2025 by AviadoBio investigators and Polish study sites sets out the open-label, ascending-dose design and reports preliminary safety in the first completed cohort of three patients, followed for up to 39, 26 and 12 weeks respectively. The authors report no clinically significant safety findings, serial safety MRI without significant haemorrhage, oedema or inflammation, no adverse events attributed to AVB-101 or the neurosurgical procedure, and an expected early transient peak in neurofilament light in serum and cerebrospinal fluid that trended back towards baseline. The registry record lists an actual study start of 30 August 2023 and the trial as recruiting.

The rationale for going through the skull rather than into the spinal fluid or the bloodstream is dose. The authors argue that seeding thalamic neurons, which project widely to cortex, can spread progranulin without crossing the blood-brain barrier or the pial membrane, using relatively low vector doses compared with intrathecal delivery. FTD-GRN, in which one faulty copy of the GRN gene leaves progranulin roughly halved, typically begins in midlife and has no approved disease-modifying treatment.

The field around it has thinned. Alector reported on 21 October 2025 that its Phase 3 INFRONT-3 trial of latozinemab missed its clinical co-primary endpoint despite raising progranulin, a result that separates the biomarker from benefit. Passage Bio announced on 15 May 2026 that it was closing its upliFT-D trial of the intra-cisterna-magna gene therapy PBFT02 after regulatory discussions over trial design. Other progranulin programmes continue: Denali said on 3 April 2026 that it had regained full rights to DNL593 and expected trial data by the end of 2026.